the AGT protein, a process which is stoichiometric and Clinically relevant cancer chemotherapeutic alkylating autoinactivating (6). AGT therefore confers protection against agents such as temozolomide and dacarbazine induce the mutagenic and toxic effects of alkylating agents, which apoptosis and are mutagenic via the formation of include the clinically important antitumour agents temozolom-O 6 -alkylguanine adducts in DNA. The DNA repair protein ide and 5-(3,3-dimethyltriazen-1-yl)imidazole-4-carboxamide O 6 -alkylguanine-DNA alkyltransferase (AGT) functions by (dacarbazine) (7-10). Failure of AGT to repair O 6 -methylguandealkylating such adducts and can thus prevent apoptosis ine results in O 6 -methylguanine:thymine mispairs following and mutagenesis. In attempts to maximize the clinical DNA replication and it is postulated that these mediate cell effectiveness of these alkylating agents, inhibitors of AGT death via mismatch repair (11). The DNA mismatch repair such as O 6 -benzylguanine (BeG) have been developed. We enzyme MSH2 is known to bind to and recognize O 6 -methylshow here that within murine small intestinal crypt cells, guanine:thymine mispairs and is also essential for a large BeG administration does not alter the apoptotic response to proportion of apoptosis observed in the murine small intestine the direct-acting methylating agents N-methyl-N-nitrosurea following exposure to alkylating agents (12,13). Mutations (MNU), temozolomide and N-methyl-NЈ-nitro-N-nitrosoguarise if the O 6 -methylguanine:thymine mispairs undergo further anidine. Furthermore, we show that BeG pretreatment fails rounds of replication. to elevate the mutation frequency at the murine Dlb-1 locus O 6 -benzylguanine (BeG) is a competitive and irreversible following exposure to MNU. Consistent with these results, inhibitor of AGT which acts by binding to the -CH 3 cysteine we show that intestinal AGT activity is effectively abolished acceptor site of AGT forming S-benzylcysteine (14,15). BeGby administration of 100 mg/kg temozolomide, even in bound AGT is inactive and is subsequently degraded. Cellular the absence of BeG. In contrast, pretreatment with BeG AGT activity can be restored only by de novo protein synthesis transiently abolished the apoptotic response to the methyl-(5) and its depletion by BeG has been proposed as a useful ating prodrug dacarbazine. Activation of dacarbazine to adjuvant to clinical methylating and chloroethylating agent treatits reactive intermediate has previously been shown to ment of tumours (16) . Adjuvant therapy of BeG combined with be cytochrome P450 dependent and we show here that such agents offers the potential to use lower, and hence less pretreatment of mice with the cytochrome P450 inhibitor toxic, doses of chemotherapeutic drug and may also be of benefit metyrapone also inhibits dacarbazine-induced apoptosis.
in overcoming tumour resistance associated with high levels of Thus BeG increases neither the prevalence of apoptosis AGT (17). Dacarbazine is a DNA alkylating agent used in the nor mutation frequency in the murine small intestine, but treatment of metastatic melanoma and Hodgkin's lymphoma is capable of inhibiting P450-dependent prodrug activation. (18) . It is a prodrug requiring cytochrome P450-dependent The positive implication from this study is that BeG N-demethylation to produce the active compound 5-(3-methyltreatment may not exacerbate the toxic and mutagenic triazen-1-yl)imidazole-4-carboxamide (MITC) (19, 20) . MITC effects of methylating agents within normal cells, although is also generated when temozlomide reacts spontaneously with it may engender other adverse reactions through the sup-H 2 O (21). MITC decomposes to a methylating intermediate pression of cytochrome P450-dependent processes.
common to a variety of agents that result in the methylation of DNA with subsequent consequences for cell death and mutation. One approach to directly determine the somatic in vivo Introduction mutation frequency relies upon detecting loss of function at The murine small intestine offers an ideal experimental system the polymorphic genetic locus Dlb-1 (22) . This locus deterto study both apoptosis and mutation frequency in response to mines the ability to bind the lectin from Dolichos biflorus in mouse intestinal epithelium. Mutation frequency can be scored but does not modulate the apoptotic response to temozolomide or another methylating agent, N-methyl-NЈ-nitro-N-nitrosoguanidine (MNNG), in the small intestine. Furthermore, we have shown that BeG treatment did not enhance the apoptotic response in a mismatch repair-deficient background (13). We show here that AGT plays no role in modulating the apoptotic response or mutation rate in the normal epithelium of the murine intestine following exposure to the methylating agent N-methyl-N-nitrosurea (MNU) or the apoptotic response to cisplatin or γ-irradiation, but that it blocks dacarbazine-mediated cell death.
Materials and methods

Mouse colonies
All mice were maintained under non-barrier conditions and given a standard diet and water ad libitum. Fig. 1 . The effect of BeG upon the induction of apoptosis in the murine AGT assay intestine. Cohorts of wild-type mice were treated with 100 mg/kg temozolomide, 50 mg/kg MNNG, 100 mg/kg MNU, 10 mg/kg cisplatin, 4 Mice were killed and tissues of interest removed, snap frozen in liquid Gy γ-irradiation and 150 mg/kg dacarbazine in the presence and absence of nitrogen and stored at -70°C until assayed as described previously (4). Briefly, BeG. Data show the prevalence of apoptosis 6 h after reagent administration tissue samples were defrosted and disrupted by sonication (10 s at 10 µm and 7 h after i.p. BeG (60 mg/kg). Each bar represents data from six mice. peak-to-peak, followed by 10 s at 16 µm peak-to-peak) in 1 ml of 50 mM Closed boxes, no BeG; open boxes, BeG treated. Error bars represent SEM. Tris-HCl (pH 8.3), 1 mM EDTA, 3 mM dithiothreitol containing 5 µg/ml leupeptin, after which 10 µl of phenylmethylsulphonyl fluoride (87 µg/ml in ethanol) was added. Insoluble cellular debris was removed by centrifugation of failure to repair endogenous alkylated DNA damage. To for 10 min at 13 000 r.p.m. at 4°C. Aliquots of the supernatants were incubated for 2 h at 37°C with a calf thymus DNA substrate that had been methylated test this hypothesis, apoptosis was scored over a time course modify enterocyte apoptosis following treatment with temozolMetyrapone was dissolved in PBS alone. Mice were exposed to γ-irradiation using a 137 Cs source at 0.27 Gy/min for 15 min, so that each animal received omide or MNNG (13). We report here the effect of BeG a dose of 4 Gy. administration on the apoptotic response to MNU, dacarbazine,
Apoptosis quantitation
cisplatin and γ-irradiation. These agents were chosen either to At a specified time point following reagent injection or irradiation, a minimum determine the effect of exposure to alkylating agents (MNU of three animals were killed, the small intestine removed, flushed with water and dacarbazine) or to act as negative controls (cisplatin and and fixed overnight in methocarn (4 parts methanol, 2 parts chloroform, 1 γ-irradiation). Wild-type mice were pretreated with BeG (60 part acetic acid). Haematoxylin and eosin stained sections were made and mg/kg) and 1 h later either 100 mg/kg MNU, 10 mg/kg apoptosis scored through the use of the Highly Optimised Microscope cisplatin, 150 mg/kg dacarbazine or 4 Gy of γ-irradiation Environment (HOME) as previously described (23, 24) . A minimum of fifty half-crypts were scored per animal.
were administered. Comparative data on temozolomide-and Once again, we did not observe an increase in necrosis in any of the treatment protocols, indicating that these agents were Results not killing cells through mechanisms other than apoptosis, at least within the time frame studied.
BeG does not induce apoptosis within the murine small intestine
The apoptotic response following low doses of temozolomide As previously shown, administration of 60 mg/kg BeG funcis not altered by BeG administration tionally depletes AGT activity in the small intestine for a period between 1 and 12 h post-drug administration (13). AGT
To investigate the possibility that the doses of alkylating agents used in Figure 1 were depleting cellular pools of active AGT inhibition may result in increased cell death as a consequence
-test). Temozolomide administration effectively ablates AGT activity in the intestine
One explanation for the failure to observe BeG-dependent differences in apoptosis and mutation frequency is that treatment with the methylating agent alone is sufficient to render AGT functionally inactive and that, further, BeG-mediated suppression is therefore largely irrelevant. To directly test this we exposed mice to varying doses of temozolomide and scored AGT activity in both the liver and intestine. As we have shown before, pretreatment with BeG markedly reduces resting levels of AGT activity at 6 h (13). In the liver this reduction is from 150 Ϯ 40.8 to 13.3 Ϯ 21 fmol/mg protein. In the intestine AGT activity falls from a lower resting level (45.6 Ϯ 12 fmol/ mg) to become undetectable 6 h after BeG treatment (13). The effect of exposure to increasing doses of temozolomide was indeed to reduce levels of AGT activity, as shown in Figure   Fig We have shown that exposure to BeG inhibits apoptosis induced by dacarbazine (Figure 1) . In order to study the kinetics of this inhibition a single dose of BeG (60 mg/kg) was administered to wild-type mice at time 0. Mice were then subsequently injected with 150 mg/kg dacarbazine at 0, 1, 6, 12, 24, 48 and 72 h after BeG delivery. Six hours after each dacarbazine injection, levels of apoptosis were scored in the small intestine ( Figure 5 ). Dacarbazine alone induced high levels of apoptosis with a mean of Ͼ60 apoptotic bodies per 50 half-crypts. However, between 1 and 6 h following BeG administration dacarbazine failed to induce apoptosis. This suppression was reversible, such that a normal apoptotic response was restored by 24 h. Thus, BeG administration reversibly inhibited dacarbazine-dependent apoptosis. The act- response we used the P450 inhibitor metyrapone (25) . Dacarbazine was administered 1 h following treatment with metyrapone (100 mg/kg i.p.). Metyrapone treatment significantly reduced and therefore rendering BeG treatment ineffective, very low the apoptotic response to dacarbazine (Figure 6 ), confirming doses of temozolomide (range 0.5-16 mg/kg) were administhat activation of the prodrug and the associated apoptotic tered to mice with and without BeG administration. Apoptosis response were P450 dependent (P Ͻ 0.05, Mann-Whitney Uwas scored 6 h later (Figure 2) . The rationale was that at low test). These findings indicate that BeG administration blocks doses of temozolomide not all functional AGT activity would activation of the prodrug dacarbazine, possibly by comprombe abolished by the alkylating agent and thus, if AGT could ising host P450 activity. actually alter the level of apoptosis, a difference between BeGtreated and non-treated mice may be revealed. No significant Discussion differences in the incidence of apoptosis were observed between BeG-treated and non-treated mice at any dose of
We have directly addressed the ability of BeG to alter rates of temozolomide (P Ͼ 0.07 for all doses, Mann-Whitney U-test).
apoptosis and mutation in the normal murine epithelium MNU-induced mutation frequency at the Dlb-1 locus is not following exposure to a range of different types of damage.
influenced by BeG
No induction of apoptosis was associated with BeG treatment. This excluded the possibility that either BeG itself or the Mutation rate within the murine small intestine following MNU was scored at the Dlb-1 locus using standard approaches depletion of AGT activity could result in the induction of apoptosis in the murine small intestine. Following treatment (1,22) . The mutation frequency increased with increasing doses of MNU (Figure 3 ), but prior treatment with BeG did not with BeG, and in the absence of detectable AGT activity, exposure to MNU, cisplatin and γ-irradiation all induced result in a significant elevation in the mutation frequency at activity by depleting cellular pools of unmethylated AGT, so limiting the impact of BeG pretreatment (5, 26, 27) . To address this possibility, temozolomide was administered at decreasing doses in the presence and absence of BeG. Similar levels of apoptosis were scored in both BeG-treated and BeG-untreated mice, suggesting that either ablation of AGT was occurring following exposure to very low levels of temozolomide or that BeG-mediated inactivation of AGT is irrelevant to the induction of apoptosis following alkylation damage. We further probed this question by analysing the effect of temozolomide administration upon AGT activity and established that low levels of temozolomide were effective in depleting AGT activity in the intestine. This is perhaps not surprising as resting levels within this tissue are relatively low. We also demonstrated a similar phenomenon for the liver, which is characterized by much higher basal AGT activity, although effective depletion was activity might be predicted to lead to an increase in Dlb-1 mutations. However, pretreatment of mice with BeG failed to elevate the mutation rate following MNU treatment. As with the effect of BeG treatment upon the induction of apoptosis, the observed failure to modify the mutation rate in the murine small intestine may be interpreted in several ways. First, AGT activity may not be relevant to protection against mutation in this tissue: other DNA lesions such as 3-methyladenosine could be responsible for these mutations. Second, exposure to the methylating agent alone may be sufficient to inactivate AGT, as suggested by our results following exposure to temozolomide. Third, it might be that in those cells in which Dlb-1 mutations normally arise, recovery of AGT activity chart of the prevalence of apoptotic bodies in the murine small intestine 6 h It seems likely that the second of these explanations is correct, following 150 mg/kg dacarbazine or 100 mg/kg metyrapone. The prevalence although it should be remembered that we have only established of apoptotic bodies at 6 h in dacarbazine-treated mice which were pretreated effective AGT depletion at a single time point for temozolomwith 100 mg/kg metyrapone 1 h prior to injection with dacarbazine is also shown (Met & Dac). Error bars represent SEM.
ide. Taken together, these results show that BeG pretreatment does not alter either the apoptotic response or mutation frequency in the normal epithelium of the murine small apoptosis. However, the levels of apoptosis were similar to intestine. those observed in BeG-untreated controls. Thus, BeG treatment A somewhat unexpected finding in the present study was neither reduced nor augmented the prevalence of apoptosis in that BeG administration blocks dacarbazine-induced apoptosis. the intestine following application of a variety of DNAIt is reasonable to suggest that this occurs either because AGT damaging agents.
activity is required by dacarbazine to induce apoptosis or Such a failure to modify the phenotype may have occurred because in vivo exposure to alkylating agents reduces AGT because BeG is blocking the normal metabolism of dacarbazine indicate BeG administration to be the most effective and least toxic method to achieve this. Second, BeG has been reported to increase mutation rates, chromosome aberrations and toxicity in normal cells treated with methylating or chloroethylating agents (36-38). In contradiction to these reports, we do not observe any effect upon in vivo mutation rate in these studies. Third, from the data presented here it is clear that in the murine small intestine AGT depletion does not elevate in vivo apoptotic levels following methylating DNA damage. This result has clear positive implications for the therapeutic use of BeG, in that BeG administration fails to augment cell death within normal tissues. This result may directly follow from the demonstrated ability of alkylating agents to partially suppress AGT activity and may simply reflect the low resting levels of AGT in the murine intestine. Finally, and perhaps most significantly, these data show that BeG can alter the produces, amongst 11 other base lesions, O 6 -methylguanine, the major premutagenic lesion in DNA. Dacarbazine requires oxidative N-demethylation by cytochrome P450 to form MITC, unlike temozolomide, (18, 28, 29) . This metabolic activation is mediated through the action of cytochrome P450 enzymes (20, 30) . Two observations argue in favour of the possibility that BeG is blocking the References normal metabolism of dacarbazine. First, temozolomide is able ing agents can reduce the activity of AGT, the available data
